Metabolix, Inc.  

(Public, NASDAQ:MBLX)   Watch this stock  
Find more results for MBLX
-0.030 (-4.30%)
Jul 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.66 - 0.76
52 week 0.50 - 1.94
Open 0.70
Vol / Avg. 0.00/75,452.00
Mkt cap 23.45M
P/E     -
Div/yield     -
EPS -0.92
Shares 34.99M
Beta 1.27
Inst. own 21%
May 20, 2014
Metabolix, Inc Annual Shareholder Meeting
May 14, 2014
Q1 2014 Metabolix, Inc Earnings Conference Call
May 14, 2014
Q1 2014 Metabolix, Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -762.77% -565.55%
Operating margin -763.33% -565.48%
EBITD margin - -548.28%
Return on average assets -148.10% -76.03%
Return on average equity -193.68% -90.07%
Employees 93 -
CDP Score - -


21 Erie Street
United States - Map
+1-617-5831700 (Phone)
+1-617-5831768 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Metabolix, Inc. is a bioscience company focused on delivering sustainable solutions to the plastics and chemicals industries. It has focused on a family of biopolymers found in nature called polyhydroxyalkanoates (PHAs), which occur naturally in living organisms and are chemically similar to polyesters. It has demonstrated the production of PHAs at industrial scale to produce PHA biopolymers and PHA precursors to biobased industrial chemicals. The Company has also demonstrated the production of polyhydroxybutyrate (PHB), a subclass of PHAs, in agriculturally non-food crops. For the Company�s second platform, it is developing C4 and C3 chemicals from biobased sources, as opposed to the fossil fuels that are used to produce industrial chemicals. Its process for creating biobased industrial C4 and C3 chemicals involves engineering metabolic pathways into microbes that, in a fermentation process, produce specific PHA structures that serve as precursors for these chemicals.

Officers and directors

Joseph H. Shaulson President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Joseph D. Hill Chief Financial Officer, Treasurer
Age: 50
Bio & Compensation  - Reuters
Johan van Walsem Chief Operating Officer
Age: 50
Bio & Compensation  - Reuters
Lynne H. Brum Vice President - Marketing and Corporate Communications
Age: 49
Bio & Compensation  - Reuters
Robert E. Engle Vice President - Business and Commercial Development, Biopolymers
Age: 50
Bio & Compensation  - Reuters
Max Senechal Vice President - Biobased Chemicals
Age: 49
Bio & Compensation  - Reuters
Oliver P. Peoples Ph.D. Vice President - Research & Development, Chief Scientific Officer, Director
Age: 55
Bio & Compensation  - Reuters
Sarah P. Cecil General Counsel, Secretary
Age: 61
Bio & Compensation  - Reuters
Peter N. Kellogg Independent Director
Age: 58
Bio & Compensation  - Reuters
Celeste B. Mastin Independent Director
Age: 44
Bio & Compensation  - Reuters